Garcia VC, Mansfield C, Leach C, Pierce A, Smith JC, Afonso M. Patient and caregiver preferences for hemophilia treatments: a discrete-choice experiment. Haemophilia. 2024 Mar;30(2):375-87. doi: 10.1111/hae.14928
Sansom SL, Hicks KA, Carrico J, Jacobson EU, Shrestha RK, Green TA, Purcell DW. Optimal allocation of societal HIV prevention resources to reduce HIV incidence in the United States. Am J Public Health. 2021 Jan;111(1):150-8. doi: 10.2105/AJPH.2020.305965
Bell T, Hill N, Mogle J, Sweeder L, Bhargava S. Longitudinal evaluation of perceived stress and memory complaints in the Einstein Aging Study. Anxiety Stress Copin. 2021 Jan;34(1):37-50. doi: 10.1080/10615806.2020.1836621
Lupo PJ, Danysh HE, Symanski E, Langlois PH, Cai Y, Swartz MD. Neighborhood-based socioeconomic position and risk of oral clefts among offspring. Am J Public Health. 2015 Dec;105(12):2518-25. doi: 10.2105/AJPH.2015.302804
Earnshaw SR, Graham CN, McDade CL, Spears JB, Kessler CM. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia. 2015 May;21(3):310-9. doi: 10.1111/hae.12621
Kruse-Jarres R, Gilsenan AW, Spears J, Kaye JA. Prospective, observational study of plasma-derived factor VIII/von Willebrand factor in immune tolerance induction: the PRISM registry. Haemophilia. 2015 Mar;21(2):e122-4. doi: 10.1111/hae.12590
DiBenedetti DB, Coles TM, Sharma T, Pericleous L, Kulkarni R. Assessing patients' and caregivers' perspectives on stability of factor VIII products for haemophilia A: a web-based study in the United States and Canada. Haemophilia. 2014 Jul;20(4):e296-303. doi: 10.1111/hae.12459
Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D. Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin. J Viral Hepat. 2012 Feb;19(2):94-102.
Brown TM, Pashos CL, Joshi AV, Lee WC. The perspective of patients with haemophilia with inhibitors and their care givers: preferences for treatment characteristics. Haemophilia. 2011 May 1;17(3):476-82.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life and productivity impact in haemophilia patients with inhibitors. Haemophilia. 2009 Jul 1;15(4):911-7.
Lee WC, Joshi AV, Woolford S, Sumner M, Brown TM, Hadker N, Pashos CL. Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: a discrete choice experiment. Haemophilia. 2008 May 1;3(14):454-65.
Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health. 2005 Jan 1;95(Suppl 1):S144-150.
Bauman KE, Foshee VA, Ennett ST, Pemberton M, Hicks KA, King TS, Koch GG. The influence of a family program on adolescent tobacco and alcohol use. Am J Public Health. 2001 Apr 1;91(4):604-10.
Rothman KJ, Cann CI, Fried MP. Carcinogenicity of dark liquor. Am J Public Health. 1989 Nov;79(11):1516-20.
Flanders WD, Rothman KJ. Occupational risk for laryngeal cancer. Am J Public Health. 1982 Apr 1;72(4):369-72.
Walker AM, Dreyer NA, Friedlander E, Loughlin JE, Rothman KJ, Kohn HI. An independent analysis of the National Cancer Institute study of non-nutritive sweeteners and bladder cancer. Am J Public Health. 1982 Apr;72(4):376-81.
Mackay AM, Rothman KJ. The incidence and severity of burn injuries following Project Burn Prevention. Am J Public Health. 1982 Mar;72(3):248-52.
Jick H, Walker AM, Rothman KJ. The epidemic of endometrial cancer: a commentary. Am J Public Health. 1980 Mar;70(3):264-7.